| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8963865 | Diabetes & Metabolism | 2018 | 7 Pages |
Abstract
In comparison to other oral glucose-lowering agents, DPP-4 inhibitor treatment did not increase overall risk of DR. However, DPP-4 inhibitors may be associated with an increased risk of retinopathy events early in the treatment phase.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
N.H. Kim, J. Choi, N.H. Kim, K.M. Choi, S.H. Baik, J. Lee, S.G. Kim,